Safety and efficacy of combined use of sildenafil, bosentan, and iloprost before and after liver transplantation in severe portopulmonary hypertension

Liver Transplantation

Volumn 14, Issue 3, 2008, Pages 287-291

  Austin, Mark J ^a   McDougall, Neil I ^b   Wendon, Julia A ^a   Sizer, Elizabeth ^a   Knisely, Alex S ^a   Rela, Mohammed ^a   Wilson, Carol ^b   Callender, Michael E ^b   O'Grady, John G ^a   Heneghan, Michael A ^a  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

^b ROYAL VICTORIA HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BOSENTAN; DOBUTAMINE; GANCICLOVIR; ILOPROST; PROSTACYCLIN; SILDENAFIL; STEROID; TACROLIMUS;

ABDOMINAL PAIN; ADULT; ARTICLE; CADAVER DONOR; CASE REPORT; CYTOMEGALOVIRUS INFECTION; DISEASE SEVERITY; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; ELECTROCARDIOGRAPHY; HEART CATHETERIZATION; HEART RIGHT VENTRICLE HYPERTROPHY; HUMAN; HYPERBILIRUBINEMIA; KIDNEY DYSFUNCTION; LEG EDEMA; LIVER TRANSPLANTATION; LOW DRUG DOSE; LUNG ARTERY PRESSURE; LUNG VASCULAR RESISTANCE; MALE; MONOTHERAPY; OXYGEN SATURATION; PORTOPULMONARY HYPERTENSION; POSTOPERATIVE CARE; PREOPERATIVE CARE; PRIORITY JOURNAL; SEPSIS; SPLENOMEGALY; THORAX PAIN; THROMBOCYTOPENIA; TRANSTHORACIC ECHOCARDIOGRAPHY;

ADULT; BLOOD PRESSURE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; DRUG TOXICITY; HUMANS; HYPERTENSION, PORTAL; HYPERTENSION, PULMONARY; ILOPROST; LIVER DISEASES; LIVER TRANSPLANTATION; MALE; PIPERAZINES; PULMONARY ARTERY; PURINES; SEVERITY OF ILLNESS INDEX; SULFONAMIDES; SULFONES; TREATMENT OUTCOME; VASODILATOR AGENTS;

EID: 41149138871     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.21310     Document Type: Article

References (28)

1. Krowka MJ, Plevak D. The distinct concepts and implications of hepatopulmonary syndrome and portopulmonary hypertension. Crit Care Med 2005;33:470.
2. Colle IO, Moreau R, Godinho E, Belghiti J, Ettori F, Cohen-Solal A, et al. Diagnosis of portopulmonary hypertension in candidates for liver transplantation: a prospective study. Hepatology 2003,37:401-409.
3. Krowka MJ, Mandell MS, Ramsay MA, Kawut SM, Fallon MB, Manzarbeitia C, et al. Hepatopulmonary syndrome and portopulmonary hypertension: a report of the multi-center liver transplant database. Liver Transpl 2004;10: 174-182.
4. Kuo PC, Plotkin JS, Gaine S, Schroeder RA, Rustgi VK, Rubin LJ, Johnson LB. Portopulmonary hypertension and the liver transplant candidate. Transplantation 1999;67: 1087-1093.
5. Hoeper MM, Krowka MJ, Strassburg CP. Portopulmonary hypertension and hepatopulmonary syndrome. Lancet 2004;363:1461-1468.
6. Fallon MB. Mechanisms of pulmonary vascular complications of liver disease: hepatopulmonary syndrome. J Clin Gastroenterol 2005;39:S138-S142.
7. Fallon MB, Abrams GA. Pulmonary dysfunction in chronic liver disease. Hepatology 2000;32:859-865.
8. Plevak D, Krowka M, Rettke S, Dunn W, Southorn P. Successful liver transplantation in patients with mild to moderate pulmonary hypertension. Transplant Proc 1993;25: 1840.
9. Benjaminov FS, Prentice M, Sniderman KW, Siu S, Liu P, Wong F. Portopulmonary hypertension in decompensated cirrhosis with refractory ascites. Gut 2003;52:1355-1362.
10. Fallon MB. Portopulmonary hypertension: new clinical insights and more questions on pathogenesis. Hepatology 2003;37:253-255.
11. Fallon MB. Hepatopulmonary syndrome: more than just a matter of tone? Hepatology 2006;43:912-914.
12. Kulkarni SK, Patil CS. Phosphodiesterase 5 enzyme and its inhibitors: update on pharmacological and therapeutical aspects. Methods Find Exp Clin Pharmacol 2004:26: 789-799.
13. Reichenberger F, Voswinckel R, Steveling E, Enke B, Kreckel A, Olschewski H, et al. Sildenafil treatment for portopulmonary hypertension. Eur Respir J 2006;28:563-567.
14. Rubin LJ, Badesch DB, Barst RJ, Galie N, Black CM, Keogh A, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002;346:896-903.
15. Hoeper MM, Halank M, Marx C, Hoeffken G, Seyfarth HJ, Schauer J, et al. Bosentan therapy for portopulmonaxy hypertension. Eur Respir J 2005;25:502-508.
16. Ramsay MA, Simpson BR, Nguyen AT, Ramsay KJ, East C, Klintmalm GB. Severe pulmonary hypertension in liver transplant candidates. Liver Transpl Surg 1997;3:494-500.
17. Budhiraja R, Hassoun PM. Portopulmonary hypertension: a tale of two circulations. Chest 2003;123:562-576.
18. Shi-Wen X, Rodriguez-Pascual F, Lamas S, Holmes A, Howat S, Pearson JD, et al. Constitutive ALK5-independent c-Jun N-terminal kinase activation contributes to endothelin-1 overexpression in pulmonary fibrosis: evidence of an autocrine endothelin loop operating through the endothelin A and B receptors. Mol Cell Biol 2006;26: 5518-5527.
19. Ling Y, Zhang J, Luo B, Song D, Liu L, Tang L, et al. The role of endothelin-1 and the endothelin B receptor in the pathogenesis of hepatopulmonary syndrome in the rat. Hepatology 2004;39:1593-1602.
20. Vincent JA, Ross RD, Kassab J, Hsu JM, Pinsky WW. Relation of elevated plasma endothelin in congenital heart disease to increased pulmonary blood flow. Am J Cardiol 1993;71:1204-1207.
21. Findlay JY, Plevak DJ, Krowka MJ, Sack EM, Porayko MK. Progressive splenomegaly after epoprostenol therapy in portopulmonary hypertension. Liver Transpl Surg 1999; 5:362-365.
22. Johnson RF, Loyd JE, Mullican AL, Fink CA, Robbins IM. Long-term follow-up after conversion from intravenous epoprostenol to oral therapy with bosentan or sildenafil in 13 patients with pulmonary arterial hypertension. J Heart Lung Transplant 2007;26:363-369.
23. Rubin LJ, Roux S. Bosentan: a dual endothelin receptor antagonist. Expert Opin Investig Drugs 2002;11:991-1002.
24. Dingemanse J, van Giersbergen PL. Clinical pharmacology of bosentan, a dual endothelin receptor antagonist. Clin Pharmacokinet 2004;43:1089-1115.
25. Fattinger K, Funk C, Pantze M, Weber C, Reichen J, Stieger B, Meier Pd. The endothelin antagonist bosentan inhibits the canalicular bile salt export pump: a potential mechanism for hepatic adverse reactions. Clin Pharmacol Ther 2001;69:223-231.
26. Mano Y, Usui T, Kamimura. H. Effects of bosentan, an endothelin receptor antagonist, on bile salt export pump and multidrug resistance-associated protein 2. Biopharm Drug Dispos 2007;28:13-18.
27. Kuntzen C, Gulberg V, Gerbes AL. Use of a mixed endothelin receptor antagonist in portopulmonary hypertension: a safe and effective therapy? Gastroenterology 2005; 128:164-168.
28. Barth F, Gerber PJ, Reichen J, Dufour JF, Nicod LP. Efficiency and safety of bosentan in Child C cirrhosis with portopulmonary hypertension and renal insufficiency. Eur J Gastroenterol Hepatol 2006:18:1117-1119.